Feb
16
$501.3M for Boston Scientific
Posted by Dirk Avery at 7:49 am under Litigation, Patent.
Perhaps the company should consider becoming a 501(c)(3)…
A federal judge added $69.4 million in pre-judgment interest to the $431.9 million a jury ordered Boston Scientific Corp. (BSX) to pay for infringing on a radiologist’s patent on drug-eluting coronary stents…
Stents are tiny scaffolds used to prop open arteries clogged by heart disease. Sales of drug-coated stents - the most profitable kind, which are coated with drugs to prevent reclogging - have waned in recent quarters amid fears that they were leading to blood clots, and a study questioned their need in certain patients. But recent studies have cast coated stents in a more favorable light, potentially easing safety worries and giving way to hopes that the market was starting to improve.